<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600444</url>
  </required_header>
  <id_info>
    <org_study_id>KSC01/08</org_study_id>
    <nct_id>NCT00600444</nct_id>
  </id_info>
  <brief_title>PORTAS 2, Comparing Venae Sectio Versus Punction of Vena Subclavia for Insertion of a Totally Implantable Access Port</brief_title>
  <acronym>PORTAS2</acronym>
  <official_title>Randomized Controlled Trial Comparing Venae Sectio Versus Punction of Vena Subclavia for Insertion of a Totally Implantable Access Port</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate if the success rate of punction the vena
      subclavia (99% in retrospective studies) will be 15% higher than the success rate of venae
      sectio (80% in retro and prospective studies) for implantation of a totally implantable
      access ports.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary success rate of the randomized intervention</measure>
    <time_frame>Assessed on the day of surgery (day 0)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peri-/postoperative complication rate for the randomized intervention</measure>
    <time_frame>Assessed after 90 day post operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Venae Sectio technique will be used to insert totally implantable access port (TIAP) by a surgeon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Punction of Vena Subclavia will be used to insert totally implantable access port (TIAP) by a radiologist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Venae sectio</intervention_name>
    <description>surgical preparation of the cephalic vene to insert a totally implantable access port.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Punction of V. subclavia</intervention_name>
    <description>radiological punction of the v. subclavia with Seldinger technique to implant a totally implantable access port</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age equal or greater than 18 years

          -  Patients scheduled for primary elective implantation of TIAP

        Exclusion Criteria:

          -  Participation in another clinical trial which could interfere with the primary
             endpoint of this study

          -  Lack of compliance

          -  Impaired mental state or language problem

          -  Patients with known allergy to contrast agent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus W Büchler, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Heidelberg, Department of General, Visceral and Transplantation Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden Würtemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2008</study_first_submitted>
  <study_first_submitted_qc>January 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2008</study_first_posted>
  <last_update_submitted>January 26, 2010</last_update_submitted>
  <last_update_submitted_qc>January 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. M. W. Büchler, Chairman Department of Surgery</name_title>
    <organization>University of Heidelberg, Department of General, Visceral and Transplantation Surgery</organization>
  </responsible_party>
  <keyword>permanent venous access</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>parenteral nutrition</keyword>
  <keyword>Patients with a benign and/or malignant diseases which demand a safe and permanent venous access, e.g. for chemotherapy and/or parenteral nutrition</keyword>
  <keyword>benign diseases</keyword>
  <keyword>malignant diseases</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

